English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background A significant percentage of patients admitted to the hospital with UTI are infected with ESBL positive and quinolone-resistant (FQ NS) enterobacteriaceae (ENT) that can complicate patient outcomes due to potentially inadequate antibiotic therapy. We used a large national multicenter database to ascertain the demography associated with susceptible and resistant UTI and the underlying comorbidities. Methods We analyzed the first positive ENT urine culture ≤3 days from admission in those with a discharge primary or secondary UTI ICD10 code from 68 US hospitals from October 1, 2015–2017 (BD Insights, Franklin Lakes, NJ). Patient demographics were identified using AHRQ classifications to assess for specific risk factors and categorized by ESBL and FQ resistance status. Healthcare-associated (HCA) episodes were defined as admissions from another care facility, admission in the prior 30 days, and presence of dialysis or cancer comorbidity. The Fisher’s exact test was used to test for significance. Results Of 16,022 adults (mean age 69.5 years; 77.7% female) with culture positive ENT UTI were identified; 11.0% (n = 1,763) were ESBL +, 31.3% (n = 5,017) were FQ NS and 8.9% (n = 1,433) being both ESBL + and FQ NS. Admissions with ESBL + /FQ NS were significantly more likely to be male, admitted with HCA risk factors and with higher important comorbidities. Demographic ESBL − /FQ S FQ NS ESBL + /FQ NS N (%) 10,784 (67.3%) 5,017 (31.3%) 1,433 (8.9%) % Male 2,252 (20.9%) 1,284 (25.6%) ¥ 401 (28.0%)* %HCA 2,716 (25.2%) 1,505 (30.3%) ^¥ 489 (34.1%)* Deficiency anemias 2,840 (26.3%) 1,563 (31.2%) ^¥ 508 (35.5%)* Renal failure 2,196 (20.4%) 1,227 (24.5%) ^¥ 402 (28.1%)* Chronic pulmonary disease 2,009 (18.6%) 1,191 (23.7%) ¥ 345 (24.1%)* Diabetes 1,947 (18.1%) 1,095 (21.8%) ¥ 318 (22.2%)* Diabetes w/ chronic complications 1,872 (17.4%) 979 (19.5%) ¥ 313 (21.8%)* Congestive heart failure 1,648 (15.3%) 1,011 (20.2%) ¥ 292 (20.4%)* * P < 0.0002 vs. ESBL-/FQ S; ^ P < 0.0032 FQ NS vs. ESBL+/FQ NS; ¥ P < 0.0012 FQ NS vs. ESBL-/FQ S. Conclusion About one in 11 admissions with UTI are ESBL + /FQ NS and are more likely to be male, with HCA risk factors and other important comorbidities. Current oral antibiotic therapy is limited in such episodes and oral treatment alternatives are needed. Disclosures J. Bruss, Alarus Development International: Employee, Salary; Spero Therapeutics: Consultant, Consulting fee. D. Melnick, Spero Therapeutics: Employee, Salary. A. Jain, Spero Therapeutics: Employee, Salary. J. Murray, Becton Dickinson and Company: Employee, Salary. I. Critchley, Spero Therapeutics: Employee, Salary. S. Kurtz, Becton Dickinson and Company: Employee, Salary. V. Gupta, Becton Dickinson and Company: Employee, Salary.

open forum infectious diseases

1504. Patient Demographics and Comorbidity Profiles Associated with Hospitalized Patients Admitted with Resistant vs. Susceptible Urinary Tract Infections (UTIs): A Multicenter Analysis